EYPT - EyePoint Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
6/30/2018
6/30/2017
Total Revenue
25,842
20,365
2,961
7,539
Cost of Revenue
3,337
2,687
-
-
Gross Profit
22,505
17,678
-
-
Operating Expense
67,159
65,539
29,235
26,115
Operating Income
-44,654
-47,861
-26,274
-18,576
Net Non Operating Interest Income Expense
-6,075
-5,122
-619
91
Other Income Expense
-
-3,810
-26,278
-
Pretax Income
-50,729
-56,793
-53,171
-18,485
Tax Provision
-
-
0
0
Net Income Common Stockholders
-50,729
-56,793
-53,171
-18,485
Diluted NI Available to Com Stockholders
-50,729
-56,793
-53,171
-18,485
Basic EPS
-
0
-0.0012
0
Diluted EPS
-
0
-0.0012
0
Basic Average Shares
-
104,307
46,226
35,344
Diluted Average Shares
-
104,307
46,226
35,344
Total Operating Income as Reported
-44,654
-47,861
-26,274
-18,576
Total Expenses
70,496
68,226
29,235
26,115
Net Income from Continuing & Discontinued Operation
-50,729
-56,793
-53,171
-18,485
Normalized Income
-50,729
-52,983
-26,893
-18,485
Interest Income
865
1,054
101
91
Interest Expense
6,940
6,176
720
-
Net Interest Income
-6,075
-5,122
-619
91
EBIT
-43,789
-50,617
-52,451
-18,576
EBITDA
-41,196
-
-
-
Reconciled Cost of Revenue
3,204
2,543
-
-
Reconciled Depreciation
2,593
2,604
1,148
815
Net Income from Continuing Operation Net Minority Interest
-50,729
-56,793
-53,171
-18,485
Total Unusual Items Excluding Goodwill
0
-3,810
-26,278
-
Total Unusual Items
0
-3,810
-26,278
-
Normalized EBITDA
-41,196
-44,203
-25,025
-17,761
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0